AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20204928 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message for high self-efficacy participants
Number of subjects: 124
Study 20204928 — intervention group
Group type: COMPARATOR
Intervention: Gain-framed message for low self-efficacy participants
Number of subjects: 124
Study 17682008 — intervention group
Group type: EXPERIMENTAL
Intervention: GONB and TPIs using lidocaine 2% and bupivacaine 0.5% + triamcinolone 40 mg
Number of subjects: 37
Study 17682008 — intervention group
Group type: COMPARATOR
Intervention: GONB and TPIs using lidocaine 2% and bupivacaine 0.5% + saline
Number of subjects: 37
Study 16620867 — intervention group
Group type: EXPERIMENTAL
Intervention: Scene analogy problems with varying relational complexity and featural distraction
Number of subjects: 5
Study 14587650 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg)
Number of subjects: 105
Study 14587650 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (12.5 mg)
Number of subjects: 105
Study 14587650 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only (Control group)
Number of subjects: 105
Study 10988306 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative autologous blood donation
Number of subjects: 10
Study 10988306 — intervention group
Group type: COMPARATOR
Intervention: Acute normovolemic hemodilution
Number of subjects: 10
Study 8971296 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin (160 mg/h)
Number of subjects: 7
Study 8971296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1361206 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg
Number of subjects: 12
Study 1361206 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg
Number of subjects: 12
Study 1361206 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 20 mg
Number of subjects: 12
Study 1361206 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 12
Study 1361206 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 12
Study 6470470 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychoeducational group intervention 'Seminars for the Separated'
Number of subjects: 314
Study 6470470 — intervention group
Group type: COMPARATOR
Intervention: Control group (married subjects)
Number of subjects: 314
Study 30113633 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1212
Study 30113633 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (MED)
Number of subjects: 1212
Study 27473400 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly payment disbursement
Number of subjects: 273
Study 27473400 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-monthly payment disbursement
Number of subjects: 273
Study 27473400 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal cheque issue)
Number of subjects: 273
Study 27473400 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention arms (monthly and semi-monthly)
Number of subjects: 273
Study 24345483 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (OBA)
Number of subjects: 85
Study 24345483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injections)
Number of subjects: 85
Study 22648836 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoplus
Number of subjects: 64
Study 22648836 — intervention group
Group type: COMPARATOR
Intervention: Lipofundin
Number of subjects: 64
Study 20495474 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site, nurse-administered intervention
Number of subjects: 163
Study 20495474 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 163
Study 18359168 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stress (Trier Social Stress Test)
Number of subjects: 40
Study 18359168 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 40
Study 16013624 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot-hole size 2.5 mm
Number of subjects: 25
Study 16013624 — intervention group
Group type: COMPARATOR
Intervention: Pilot-hole size 3.2 mm
Number of subjects: 25
Study 14564334 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy (6 weeks of intensive home-based hydrotherapy)
Number of subjects: 15
Study 10981255 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 0
Study 8888380 — intervention group
Group type: EXPERIMENTAL
Intervention: m-CPP (0.08 mg/kg)
Number of subjects: 10
Study 8888380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1285042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative autologous transfusion (IOAT)
Number of subjects: 0
Study 6591741 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 240 mg I/ml
Number of subjects: 51
Study 6591741 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 300 mg I/ml
Number of subjects: 51
Study 6591741 — intervention group
Group type: COMPARATOR
Intervention: metrizoate 200 mg I/ml
Number of subjects: 51
Study 6591741 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 240 mg I/ml and iohexol 300 mg I/ml
Number of subjects: 51
Study 31321915 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted partner notification services (aPNS)
Number of subjects: 0
Study 28387833 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (opioid antagonist)
Number of subjects: 58
Study 28387833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 27527342 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial caries removal followed by adhesive restoration
Number of subjects: 464
Study 27527342 — intervention group
Group type: COMPARATOR
Intervention: Complete caries removal followed by adhesive restoration
Number of subjects: 464
Study 27527342 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial adhesive system
Number of subjects: 464
Study 27527342 — intervention group
Group type: COMPARATOR
Intervention: Traditional two-step self-etch adhesive system
Number of subjects: 464
Study 24509027 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive, empowerment-focused, community-based health promotion program
Number of subjects: 130
Study 24509027 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 130
Study 22198776 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg rectally 30 to 60 minutes before ERCP plus somatostatin 0.25 mg/h for 6 hours
Number of subjects: 540
Study 22198776 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository and saline solution
Number of subjects: 540
Study 21034824 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant adenovirus serotype 5 (rAd5) vaccine encoding the envelope glycoprotein (GP) from the Zaire and Sudan Ebola virus species, administered at 2×10(9) viral particles (n=12)
Number of subjects: 31
Study 21034824 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant adenovirus serotype 5 (rAd5) vaccine encoding the envelope glycoprotein (GP) from the Zaire and Sudan Ebola virus species, administered at 2×10(10) viral particles (n=11)
Number of subjects: 31
Study 21034824 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 31
Study 17413885 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominoplasty
Number of subjects: 12
Study 17413885 — intervention group
Group type: COMPARATOR
Intervention: Noninterventional group
Number of subjects: 12
Study 16669149 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fundoplicature (Group II)
Number of subjects: 285
Study 16669149 — intervention group
Group type: COMPARATOR
Intervention: Anterior partial fundoplication (Group II)
Number of subjects: 285
Study 16669149 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (both groups)
Number of subjects: 285
Study 11955470 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT
Number of subjects: 41
Study 11955470 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 41
Study 11131271 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocapril, 2 to 4 mg once daily for 12 months
Number of subjects: 76
Study 11131271 — intervention group
Group type: COMPARATOR
Intervention: Diuretic (trichlormethiazide) continued for an additional 12 months
Number of subjects: 76
Study 8825539 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration with lidocaine 1% with adrenaline 1:200,000, 0.4 ml.kg‐1 (n = 21)
Number of subjects: 43
Study 8825539 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve blockade with bupivacaine 0.5%, 0.4 ml.kg‐1 (n = 22)
Number of subjects: 43
Study 1433739 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) group
Number of subjects: 5524
Study 1433739 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) group
Number of subjects: 5524
Study 1433739 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups (SI and UC) with diastolic blood pressure maintained below 95 mm Hg
Number of subjects: 5524
Study 1433739 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with blood pressure ≥ 95 mm Hg
Number of subjects: 5524
Study 1433739 — intervention group
Group type: EXPERIMENTAL
Intervention: Black men (n = 463)
Number of subjects: 5524
Study 2990260 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation (group I)
Number of subjects: 20
Study 2990260 — intervention group
Group type: COMPARATOR
Intervention: Control group (group II)
Number of subjects: 20
Study 2990260 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received the same drugs (droperidol, flunitrazepam, pancuronium, nitrous oxide with oxygen)
Number of subjects: 20
Study 2990260 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 30096245 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose preload (200 kcal)
Number of subjects: 22
Study 30096245 — intervention group
Group type: COMPARATOR
Intervention: Sucralose preload (0 kcal)
Number of subjects: 22
Study 30096245 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game playing (30 min)
Number of subjects: 22
Study 30096245 — intervention group
Group type: COMPARATOR
Intervention: No video game playing (control condition)
Number of subjects: 22
Study 29063860 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxilaprevir (VOX) 100 mg
Number of subjects: 66
Study 29063860 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxilaprevir (VOX)
Number of subjects: 66
Study 27448838 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative educational intervention (KTFI)
Number of subjects: 100
Study 27448838 — intervention group
Group type: COMPARATOR
Intervention: Routine preoperative education (Control Group)
Number of subjects: 100
Study 25223172 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuntai Capsule (KC)
Number of subjects: 70
Study 25223172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 22578567 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal Le Fort I osteotomy (Group I)
Number of subjects: 6
Study 22578567 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal Le Fort I osteotomy without pterygomaxillary suture disjunction (Group II)
Number of subjects: 6
Study 22578567 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal Le Fort I osteotomy with pterygomaxillary suture disjunction and fixation of the anterior nasal spine with steel wire (Group III)
Number of subjects: 6
Study 20207828 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 (1.2 pmol/kg · min)
Number of subjects: 9
Study 20207828 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study 17679728 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily for 16 weeks + gefitinib 250 mg/d orally for 16 weeks
Number of subjects: 206
Study 17679728 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg daily for 16 weeks
Number of subjects: 206
Study 15671611 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m‐sestamibi imaging
Number of subjects: 29
Study 15671611 — intervention group
Group type: COMPARATOR
Intervention: PET
Number of subjects: 29
Study 11849904 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (MI)
Number of subjects: 109
Study 11849904 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 109
Study 10190536 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day simvastatin and fenofibrate therapy
Number of subjects: 0
Study 10190536 — intervention group
Group type: COMPARATOR
Intervention: Standard daily combination of simvastatin and fenofibrate
Number of subjects: 0
Study 7799040 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-dose warfarin (VLDW)
Number of subjects: 100
Study 2328303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelletised doxycycline with food
Number of subjects: 0
Study 2328303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelletised doxycycline without food
Number of subjects: 0
Study 2328303 — intervention group
Group type: COMPARATOR
Intervention: Reference product without food
Number of subjects: 0
Study 31173679 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4000 IU per day)
Number of subjects: 2423
Study 31173679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2423
Study 29045529 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI and bevacizumab (FOLFIRI/bev)
Number of subjects: 567
Study 29045529 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI and cetuximab (FOLFIRI/cet)
Number of subjects: 567
Study 29045529 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined FOLFIRI/bev cohorts
Number of subjects: 567
Study 25962515 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTIMAL (occupational therapy led self-management support programme)
Number of subjects: 50
Study 25962515 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTIMAL
Number of subjects: 50
Study 25962515 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 24021347 — intervention group
Group type: EXPERIMENTAL
Intervention: 38-h communication skills training program
Number of subjects: 80
Study 22185865 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose multidetector computed tomography (CT) screening
Number of subjects: 7557
Study 22185865 — intervention group
Group type: COMPARATOR
Intervention: Control group without screening
Number of subjects: 7557
Study 19728556 — intervention group
Group type: EXPERIMENTAL
Intervention: MetraTRAP5b assay
Number of subjects: 0
Study 19728556 — intervention group
Group type: EXPERIMENTAL
Intervention: BoneTRAP® assay
Number of subjects: 0
Study 17113671 — intervention group
Group type: EXPERIMENTAL
Intervention: Monte Carlo system (MCDE)
Number of subjects: 10
Study 17113671 — intervention group
Group type: COMPARATOR
Intervention: Superposition convolution systems (TMS and Pinnacle)
Number of subjects: 10
Study 17113671 — intervention group
Group type: EXPERIMENTAL
Intervention: All planning systems (Monte Carlo, TMS, Pinnacle)
Number of subjects: 10
Study 15310780 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic hematopoietic colony-stimulating factors (CSFs)
Number of subjects: 16
Study 15310780 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or no therapy)
Number of subjects: 16
Study 11497229 — intervention group
Group type: EXPERIMENTAL
Intervention: New cytotoxic drugs (vinorelbine, paclitaxel, docetaxel, gemcitabine, irinotecan)
Number of subjects: 0
Study 11497229 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cisplatin and newer drugs
Number of subjects: 0
Study 11497229 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and other newer drugs
Number of subjects: 0
Study 11497229 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer drug combinations
Number of subjects: 0
Study 9462204 — intervention group
Group type: EXPERIMENTAL
Intervention: LAC (30 mg of lansoprazole twice daily + 1 g of amoxycillin twice daily + 400 mg of metronidazole twice daily)
Number of subjects: 496
Study 9462204 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM (30 mg of lansoprazole twice daily + 1 g of amoxycillin twice daily + 250 mg of clarithromycin twice daily)
Number of subjects: 496
Study 9462204 — intervention group
Group type: EXPERIMENTAL
Intervention: LCM (30 mg of lansoprazole twice daily + 400 mg of metronidazole twice daily + 250 mg of clarithromycin twice daily)
Number of subjects: 496
Study 9462204 — intervention group
Group type: EXPERIMENTAL
Intervention: OAM (20 mg of omeprazole twice daily + 1 g of amoxycillin twice daily + 400 mg of metronidazole twice daily)
Number of subjects: 496
Study 7945617 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical venous pressure (UVP) measurement
Number of subjects: 113
Study 7945617 — intervention group
Group type: EXPERIMENTAL
Intervention: Preload index (PLI) assessment of reversed IVC blood flow
Number of subjects: 113
Study 7945617 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimate of abnormal UVP based on PLI
Number of subjects: 113
Study 3285732 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine/0.0002% fentanyl
Number of subjects: 80
Study 3285732 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine
Number of subjects: 80
Study 30487974 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime insulin aspart
Number of subjects: 40
Study 30487974 — intervention group
Group type: COMPARATOR
Intervention: Bedtime insulin detemir
Number of subjects: 40
Study 26837800 — intervention group
Group type: EXPERIMENTAL
Intervention: Competence feedback group (CFG)
Number of subjects: 19
Study 26837800 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 19
Study 25537011 — intervention group
Group type: EXPERIMENTAL
Intervention: Tideglusib 1000 mg QD
Number of subjects: 306
Study 25537011 — intervention group
Group type: EXPERIMENTAL
Intervention: Tideglusib 1000 mg QOD
Number of subjects: 306
Study 25537011 — intervention group
Group type: EXPERIMENTAL
Intervention: Tideglusib 500 mg QD
Number of subjects: 306
Study 25537011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 23522973 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide therapy (Samarium‐153 EDTMP), N=12
Number of subjects: 24
Study 23522973 — intervention group
Group type: COMPARATOR
Intervention: Control group (no radionuclide therapy), N=12
Number of subjects: 24
Study 20693354 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart administered 15 min before mealtime
Number of subjects: 10
Study 18439244 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of personality disorders and individual feedback
Number of subjects: 0
Study 18439244 — intervention group
Group type: COMPARATOR
Intervention: General life situation interview
Number of subjects: 0
Study 16644913 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH) performed, n = 49
Number of subjects: 103
Study 16644913 — intervention group
Group type: COMPARATOR
Intervention: Control group (no assisted hatching), n = 54
Number of subjects: 103
Study 12826500 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (administered 8 hours and 1 hour before coronary angiography)
Number of subjects: 80
Study 12826500 — intervention group
Group type: COMPARATOR
Intervention: Control (no captopril treatment)
Number of subjects: 80
Study 11196396 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day for 1 week, increased to 40 mg/day for the following weeks
Number of subjects: 43
Study 11196396 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day plus local application of lidocaine ointment
Number of subjects: 43
Study 11196396 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine alone
Number of subjects: 43
Study 11196396 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine plus lidocaine ointment
Number of subjects: 43
Study 8992100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 8 mg/kg bodyweight once daily for 5 days
Number of subjects: 160
Study 8992100 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 20,000 I.U./kg bodyweight t.i.d. for 10 days
Number of subjects: 160
Study 2001019 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane 0.65 MAC
Number of subjects: 28
Study 2001019 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane 0.65 MAC
Number of subjects: 28
Study 2001019 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane 1.25 MAC
Number of subjects: 28
Study 2001019 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane 1.25 MAC
Number of subjects: 28
Study 6678822 — intervention group
Group type: EXPERIMENTAL
Intervention: Centbucridine (0.5%)
Number of subjects: 120
Study 6678822 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (2%)
Number of subjects: 120
Study 30088055 — intervention group
Group type: EXPERIMENTAL
Intervention: LAL ablation
Number of subjects: 102
Study 30088055 — intervention group
Group type: COMPARATOR
Intervention: Control (EEPVI and roof line ablation)
Number of subjects: 102
Study 30088055 — intervention group
Group type: EXPERIMENTAL
Intervention: LAL group
Number of subjects: 102
Study 30088055 — intervention group
Group type: EXPERIMENTAL
Intervention: LAL group (without dyssynchrony)
Number of subjects: 102
Study 30088055 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 30088055 — intervention group
Group type: EXPERIMENTAL
Intervention: LAL group (with dyssynchrony)
Number of subjects: 102
Study 28629243 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 120
Study 28629243 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 120
Study 27232378 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 9
Study 24755906 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times a day for 3 days)
Number of subjects: 28
Study 24755906 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 28
Study 22640466 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 881
Study 22640466 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 881
Study 20586522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (300, 450, and 600 mg daily)
Number of subjects: 0
Study 20586522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0